Amryt Pharma Plc Revenue Growth Rates (AMYT), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Amryt Pharma Plc  (NASDAQ: AMYT)
 

AMYT's Revenue Growth by Quarter and Year

Amryt Pharma Plc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AMYT Revenue (in millions $) FY 2021 FY 2020 FY 2019 FY 2018
4th Quarter December 222.54
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 222.54





AMYT Revenue fourth quarter 2021 Y/Y Growth Comment
Amryt Pharma Plc in the fourth quarter 2021 achieved Revenue of $ 222.54 millions compare to recorded in same quarter a year ago.

Looking into fourth quarter 2021 results within Major Pharmaceutical Preparations industry 114 other companies have achieved higher Revenue growth. While Amryt Pharma Plc' s Revenue no change of 0% ranks overall at the positon no. 1865 in the fourth quarter 2021.


AMYT Revenue ( Y/Y Growth %) 2021
 2020 2019 2018
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   - - - -

Financial Statements
Amryt Pharma Plc's fourth quarter 2021 Revenue $ 222.54 millions AMYT's Income Statement
Amryt Pharma Plc's fourth quarter 2020 Revenue $ 0.00 millions Quarterly AMYT's Income Statement


AMYT Revenue (Quarter on Quarter Growth %)

 2021
 2020 2019 2018
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   - - - -


Back to AMYT Growth rate Comparisons >> Back to AMYT Growth rate Comparisons >>


Revenue fourth quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #115
Healthcare Sector #301
Overall #1865

Revenue Y/Y Growth Statistics
High Average Low
21.87 % 21.87 % 21.87 %
(Dec 31 2021)  
Revenue fourth quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #115
Healthcare Sector #301
Overall #1865
Revenue Y/Y Growth Statistics
High Average Low
21.87 % 21.87 % 21.87 %
(Dec 31 2021)  

Revenue by Quarter for the Fiscal Years 2018, 2019, 2020, 2021

Amryt Pharma Plc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


AMYT's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


AMYT's IV. Quarter Q/Q Revenue Comment


Amryt Pharma Plc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2021)		 12 Months Ending
 12 Months Ending
 12 Months Ending
 12 Months Ending
Cumulative Revenue 12 Months Ending $ 222.54 $ 0.00 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) 21.87 % - - - -
Year on Year Revenue Growth Overall Ranking # 1865 # 0 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 21.87 % - - - -
Seq. Revenue Growth (TTM) Overall Ranking # 1865 # 0 # 0 # 0 # 0


Cumulative Revenue growth Comment
With 21.87% annual Revenue growth, Amryt Pharma Plc would report a record annual Revenue rise if the fiscal year would end on Dec 31 2021.

In the Healthcare sector 300 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 1865.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 115
Healthcare Sector # 301
Overall # 1865

Revenue TTM Y/Y Growth Statistics
High Average Low
21.87 %
 21.87 %
21.87 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 115
Sector # 301
S&P 500 # 1865
Cumulative Revenue growth Comment
With 21.87% annual Revenue growth, Amryt Pharma Plc would report a record annual Revenue rise if the fiscal year would end on Dec 31 2021.

In the Healthcare sector 300 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 1865.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 115
Healthcare Sector # 301
Overall # 1865

Revenue TTM Y/Y Growth Statistics
High Average Low
21.87 %
21.87 %
21.87 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 115
Sector # 301
S&P 500 # 1865




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
AMYT's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Dec 31 2021 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2021
Regenerx Biopharmaceuticals inc -0.01%$ -0.005 millions
Xtant Medical Holdings Inc -0.32%$ -0.321 millions
Biomarin Pharmaceutical Inc-0.51%$ -0.510 millions
Organon and Co -0.62%$ -0.620 millions
Healthcare Services Group Inc -0.65%$ -0.645 millions
Bausch Health Companies Inc -0.77%$ -0.768 millions
Tenet Healthcare Corp-1.20%$ -1.200 millions
Rockwell Medical inc -1.20%$ -1.203 millions
China Pharma Holdings Inc-1.42%$ -1.424 millions
Mimedx Group Inc -1.66%$ -1.662 millions
Adm Tronics Unlimited Inc -1.70%$ -1.703 millions
Marinus Pharmaceuticals Inc -1.75%$ -1.745 millions
Reshape Lifesciences Inc-2.00%$ -1.996 millions
Bicycle Therapeutics Plc-2.00%$ -2.001 millions
Zimmer Biomet Holdings Inc -2.27%$ -2.273 millions
Elanco Animal Health Incorporated-2.34%$ -2.343 millions
Gilead Sciences Inc -2.39%$ -2.385 millions
Axogen inc -2.95%$ -2.948 millions
Acorda Therapeutics Inc -3.12%$ -3.124 millions
Veru Inc -3.30%$ -3.297 millions
Neuronetics Inc -3.58%$ -3.575 millions
Biogen Inc -4.16%$ -4.165 millions
Inmed Pharmaceuticals Inc-4.23%$ -4.230 millions
Pharming Group N v -4.38%$ -4.378 millions
Notable Labs Ltd -4.39%$ -4.390 millions
Semler Scientific inc -4.40%$ -4.398 millions
Cv Sciences Inc -4.42%$ -4.424 millions
Meridian Bioscience Inc -4.92%$ -4.925 millions
Aclaris Therapeutics Inc -5.00%$ -5.000 millions
Sight Sciences Inc -5.18%$ -5.179 millions


About Amryt Pharma Plc Revenue Growth Rates (AMYT), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Amryt Pharma Plc (CIK 1783010).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001140361-22-016877
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Amryt Pharma Plc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.